Clinical Trial Update: Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone [Phase 2]

View source ↗

Summary

Phase 2 study evaluating atrasentan with Zometa in men with prostate cancer metastatic to bone has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Prostate Cancer

Drugs mentioned

• Atrasentan (atrasentan)
• Zometa (Zoledronic acid)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Prostate Cancer, Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED